CLOs on the Move

Alexion Pharmaceuticals

www.alexion.com

 
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Our shared purpose to serve patients in need drives us to find answers, change the world, and create a legacy. Alexion`s three highly innovative therapies treat patients with four severe and ultra-rare diseases, and we are committed to developing additional therapies that have the potential to transform patients` lives. Today, Alexion is advancing the most robust rare disease pipeline in the biotech industry, which, in addition to our complement and metabolic clinical programs, includes more than 30 diverse preclinical programs across ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.alexion.com
  • 100 College Street
    New Haven, CT USA 06510
  • Phone: 203.271.8198

Executives

Name Title Contact Details
Eric Rogers
 Vice President, Ethics and Compliance Profile
David King
 Executive Director, Head of US Compliance Profile
Piyush Sharma
 Senior Vice President and Head of Compliance Profile
Piyush Sharma
 SVP, Head of Compliance, Alexion ... Profile
Sagun KC
 Director and IP Counsel Profile

Similar Companies

Alpine Biomed

Alpine Biomed is a Fountain Valley, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development.

480 Biomedical

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery.

Medallion Laboratories

Medallion Laboratories is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Nkmax

NKMax America is harnessing the power of the body`s immune system through the development of unique Natural Killer (NK) cell therapies. NK cell adoptive immunotherapy enhances a patient`s ability to destroy abnormal cells.